IL3 and chronic myelogenous leukemia, BCR-ABL1 positive: The resulting formulations, IL3-Exo-Imatinib and IL3-Exo-BCR-ABL siRNA demonstrated specific targeting ability against CML cells and effectively inhibited cancer cell growth both in vitro and in vivo [227].